Annexon Biosciences is a technology company.
Annexon Biosciences has raised $219.0M across 3 funding rounds.
Annexon Biosciences has raised $219.0M in total across 3 funding rounds.
Annexon Biosciences is a clinical-stage biopharmaceutical company developing complement medicines targeting the classical complement pathway, initiated by aberrant C1q activation, to treat autoimmune, neurodegenerative, and ophthalmic disorders.[1][2][3] Its lead product candidates include ANX005 (intravenous for Guillain-Barré syndrome), ANX007 (intravitreal for geographic atrophy), and ANX1502 (oral small molecule for autoimmune diseases), serving patients in healthcare with a biomarker-driven strategy to block C1q and improve treatment outcomes.[1][2] The company demonstrates growth momentum through planned 2025 milestones, such as a Biologics License Application submission for ANX005 in H1 2025, Phase 3 enrollment completion for ANX007 in H2 2025, and advancing ANX1502 across indications.[1]
Founded in 2011 and headquartered in Brisbane, California, Annexon Biosciences emerged from scientific insights into the classical complement pathway, co-founded by Dr. Ben Barres, a prominent neuroscientist whose work highlighted C1q's role in neurodegenerative diseases.[1][3][4] The idea stemmed from targeting C1q—the initiating molecule of the classical complement pathway—to halt damaging immune responses in diseases of the body, brain, and eye, building on research into complement-mediated disorders.[2][3] Early traction included developing a platform technology, filing 29 patents (focused on complement system, immune system, and immunology), and advancing a pipeline with innovative inhibitors like ANX005, ANX007, and ANX009.[1][2]
Annexon rides the wave of precision immunology in biopharma, targeting the classical complement pathway amid rising demand for therapies in underserved areas like Guillain-Barré syndrome, geographic atrophy, and autoimmune disorders, where current treatments fall short.[1][2][3] Timing aligns with advancing clinical data—such as Phase 2 vision preservation results for ANX007 and 2025 regulatory filings—fueled by market forces like aging populations driving neurodegenerative and ophthalmic needs, plus growing recognition of complement's role in disease.[1] It influences the ecosystem by pioneering C1q inhibition, inspiring biomarker strategies, and contributing publications that advance complement research, potentially reshaping standards of care in neurology and ophthalmology.[1][4]
Annexon is poised for pivotal 2025 catalysts, including ANX005 BLA submission, ANX007 Phase 3 enrollment, and ANX1502 expansion, with Phase 3 data expected in 2026, potentially accelerating approvals and partnerships.[1] Trends like oral complement inhibitors and neurodegeneration focus will shape its path, evolving its influence from clinical innovator to commercial leader in complement-mediated therapies. This positions Annexon to deliver on its mission of transformative medicines, directly addressing unmet needs in devastating diseases.[3]
Annexon Biosciences has raised $219.0M in total across 3 funding rounds.
Annexon Biosciences's investors include James Barrett.
Annexon Biosciences has raised $219.0M across 3 funding rounds. Most recently, it raised $100.0M Series C in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $100.0M Series C | James Barrett | |
| Dec 1, 2018 | $75.0M Series C | James Barrett | |
| Jun 1, 2016 | $44.0M Series B | James Barrett |